View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress

DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress Châtillon, France, February 25, 2025 DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the company will participate in the American Academy of Allergy, Asthma, and Immunology and World Allergy Organization (AAAAI/WAO) Joint Congress, February 28-March 3, 2025, in San Diego, CA. An oral abstract presentation by Dr. David Fleischer, FAAAAI, FACAAI, Profess...

 PRESS RELEASE

DBV Technologies participera au prochain congrès conjoint AAAAI/WAO

DBV Technologies participera au prochain congrès conjoint AAAAI/WAO Châtillon, France, le 25 février (22 :30 CEST) 2025 DBV Technologies participera au prochain congrès conjoint AAAAI/WAO DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), une société biopharmaceutique au stade clinique a annoncé aujourd'hui que la société participerait au congrès conjoint de l'American Academy of Allergy, Asthma, and Immunology et de la World Allergy Organization (AAAAI/WAO), qui se tiendra du 28 février au 3 mars 2025 à San Diego (Californie). David Fleischer, FAAAAI, FA...

 PRESS RELEASE

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO ...

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF AMF Regulated InformationChâtillon, France, January 13, 2025 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF. Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appeared on the liquidity account as of December 31, 2024: 266,868 DBV Technologies shares,€...

 PRESS RELEASE

Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BH...

Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF Informations RéglementéesChâtillon, France, le 13 janvier 2025 Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq : DBVT), laboratoire biopharmaceutique français, publie aujourd’hui le bilan semestriel de son contrat de liquidité avec ODDO BHF. Au titre du contrat de liquidité confié à ODDO BHF, portant sur les actions de la société DBV TECHNOLOGIES, à la date du 31 décembre 2024, les moyens suivants figuraient au compte de liquidité...

Brian Moretta ... (+3)
  • Brian Moretta
  • Mark Thomas
  • Martin Hall

Hardman & Co Monthly: January 2025

Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to monitor the performance, and to highlight the attractiveness, of life sciences investments over the long term, and to try to identify those stocks that have disruptive technologies that consistently allow them to outperform both the index and the markets. Many of the 53 constituents of the index are high-risk, with micro-capitalisations and a long way from pro...

Martin Hall
  • Martin Hall

Hardman & Co Healthcare Index: 2024 – Tough year for Life Sciences

The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the third year running, despite generally good returns in global markets, particularly in the US, performance in 2024 was poor, not helped by the capital-intensive nature of the sector. The HHI fell 17.7% to 398.9, underperforming all its benchmarks – FTSE 100 (+5.7%), FTSE All-Share (5.6%) and the FTSE AIM All-Share Index (-5...

 PRESS RELEASE

DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase ...

DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study Châtillon, France, January 8th, 2025 DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study EPITOPE OLE data demonstrates continued improvement in treatment benefit of VIASKIN® Peanut patch in toddlers 1 – 3 years through 36 months 68.2% of subjects completed the oral food challenge (~12-14 peanut kernels) without meeting stopping criteria, compared to 30.7% at month 12No treatment-related anaphylaxis or serious treatment-related Treatment-Emergen...

 PRESS RELEASE

DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway f...

DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old Châtillon, France, December 11th, 2024 DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old DBV and FDA aligned on key study design elements for the COMFORT Toddlers study in 1 – 3 year-olds, including study size and wear time collection methodology and analysis COMFORT Toddlers study on-track to initiate in 2Q 2025Viaskin Peanut patch BLA submission for the Toddlers indication anticipated ...

 PRESS RELEASE

Information regarding the total number of voting rights and  total nu...

Information regarding the total number of voting rights and  total number of shares of the Company as of November 30, 2024 Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights11/30/2024102,847,501Total gross of voting rights: 102,847,501Total net* of voting rights: 102,582,335 * Net total = total number of voting rights attached...

 PRESS RELEASE

Information relative au nombre total des droits de vote et d’actions ...

Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 novembre 2024                                                                Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 novembre 2024 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : NYSE Euronext Paris Code ISIN : FR 0010417345   Date   Nombre total d’actions composant le capital social Nombre total de droits de vote 30/11/2024   102.847.501   ...

 PRESS RELEASE

DBV Technologies Announces Plan to Implement ADS Ratio Change

DBV Technologies Announces Plan to Implement ADS Ratio Change Châtillon, France, November 11, 2024 DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J200), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares (the “ADS Ratio”), nominal value €0.10 (ten cents) per s...

 PRESS RELEASE

DBV Technologies Reports Third Quarter 2024 Financial Results

DBV Technologies Reports Third Quarter 2024 Financial Results Châtillon, France, November 6, 2024 DBV Technologies Reports Third Quarter 2024 Financial Results DBV closes Q3 2024 with a cash balance of $46.4 million; cash runway into Q1 2025 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J200), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter of 2024. The quarterly and nine months financial statements were approved by the Board of Directors on November 6, 2024. Financial High...

 PRESS RELEASE

DBV Technologies publie ses résultats financiers du troisième trimestr...

DBV Technologies publie ses résultats financiers du troisième trimestre 2024 Châtillon, France, le 6 novembre (22 :30 CET) 2024 DBV Technologies publie ses résultats financiers du troisième trimestre 2024 DBV clôture le troisième trimestre 2024 avec un solde de trésorerie de 46,4 $ millions permettant de financer l’activité jusqu'au premier trimestre 2025 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J200), une société biopharmaceutique au stade clinique spécialisée dans les options de traitement des allergies alimentaires et ...

 PRESS RELEASE

DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patc...

DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe Châtillon, France, October 22, 2024 DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe DBV to pursue an Accelerated Approval pathway for toddlers ages 1 – 3 years-old BLA submission under Accelerated Approval is subject to completion of a six-month supplemental safety study in toddlers to be initiated in Q2 2025VITESSE Phase 3 study evaluating the Viaskin Peanut patch in children ages 4 – 7 years-old exceeded enrollment goals; Toplin...

 PRESS RELEASE

DBV annonce des avancées règlementaires positives pour le patch Viaski...

DBV annonce des avancées règlementaires positives pour le patch Viaskin® Peanut aux États-Unis et en Europe Châtillon, France, le 22 octobre (22 :15 CEST) 2024 DBV annonce des avancées règlementaires positives pour le patch Viaskin® Peanut aux États-Unis et en Europe Procédure d'approbation accélérée aux Etats-Unis pour les enfants âgés de 1 à 3 ans.Dépôt du BLA dans le cadre de l'approbation accélérée conditionnée à la réalisation d'une étude d’innocuité supplémentaire de six mois chez les enfants âgés 1-3 ans, initiée au deuxième trimestre 2025.Objectifs de recrutement dépassés pour l'...

 PRESS RELEASE

DBV Technologies to Participate in Upcoming ACAAI 2024 Congress

DBV Technologies to Participate in Upcoming ACAAI 2024 Congress Châtillon, France, October 18, 2024 DBV Technologies to Participate in Upcoming ACAAI 2024 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, October 24 – 28th, 2024 in Boston, Massachusetts. This year’s meeting will feature a “Product Theater” on What Defines an Optimal Peanut Allergy Treatment? Duri...

 PRESS RELEASE

DBV Technologies participera au prochain congrès de l'ACAAI 2024

DBV Technologies participera au prochain congrès de l'ACAAI 2024 Châtillon, France, le 18 octobre (22 :30 CEST) 2024 DBV Technologies participera au prochain congrès de l'ACAAI 2024 DBV Technologies (Euronext : DBV - ISIN : FR0010417345 - Nasdaq Stock Market : DBVT), société biopharmaceutique au stade clinique, a annoncé aujourd'hui sa participation au congrès scientifique annuel de l'American College of Allergy, Asthma & Immunology (ACAAI), qui se tiendra du 24 au 28 octobre 2024 à Boston, dans le Massachusetts. Cette édition du congrès prévoit un forum sur le thème « Qu'es...

 PRESS RELEASE

Information regarding the total number of voting rights and total numb...

Information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2024 Information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights     09/30/2024       96,501,526     Total gross of voting rights: 96,501,526 Total net* of voting rights: 96,199,467 * Net total = to...

 PRESS RELEASE

Information relative au nombre total des droits de vote et d’actions c...

Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 septembre 2024 Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 septembre 2024 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : NYSE Euronext Paris Code ISIN : FR 0010417345 DateNombre total d’actionscomposant le capital socialNombre total de droits de vote  30/09/2024   96 501 526 Total brut des droits de vote : 96 501 526Total net* des droits de vote : 96 199 467 *Total net = nombre tota...

Hybridan Small Cap Feast - 1 October 2024

1st October 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced, or it is a rumour Dish of the day Admissions: None Delistings: None What’s baking in the oven? Potential**** Initial Public Offerings: ITF announced: 18th September 2024: GenIP aims to list on the AIM market on 2 October 2024. It is targeting to raise £1.5m and anticipating a £6.5m market cap. G...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch